Tags

Type your tag names separated by a space and hit enter

Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders?
Geriatr Psychol Neuropsychiatr Vieil. 2018 Mar 01; 16(1):78-86.GP

Abstract

Lithium is used as a first line treatment in bipolar disorder. The neuroprotective effects of lithium in this indication tend to be well known and are mediated by its action on two enzymes: glycogen synthase kinase-3 and inositol monophosphatase-1. Preclinical and clinical studies seek to evaluate the neuroprotective effect of lithium in neurodegenerative disorders. The aims of this literature review is to gather clinical studies that investigated the efficacy of lithium in neurodegenerative diseases, using a systematic method based on PubMed data. Results were found concerning Alzheimer's disease and related dementias, Huntington's disease, amyotrophic lateral sclerosis and spino-cerebellar ataxia. Lithium exposure showed a potential neuroprotective effect in studies on psychiatric populations with a lower prevalence of Alzheimer's disease in exposed patients. In patients with mild cognitive impairment, lithium would be associated with clinical improvement and a lower level of cerebrospinal phosphorylated tau protein. Lithium would allow at least a partial improvement in symptoms, including suicidal thoughts, in Huntington's disease. Despite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis. In spinocerebellar ataxia, introduction of lithium may be of benefits in terms of improvement of cerebellar symptoms. Large randomized controlled trials are required to asses the effect of early exposure lithium in these indications, based on reliable biological markers of disease.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Morlet É
Service de psychiatrie, Hôpital Bicêtre, HUPS, Assistance publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Hozer F
Service de psychiatrie, Hôpital Bicêtre, HUPS, Assistance publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France, Inserm UMRS 1178, CESP, Team "Depression and antidepressants", Le Kremlin-Bicêtre, France.
Costemale-Lacoste JF
Service de psychiatrie, Hôpital Bicêtre, HUPS, Assistance publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France, Inserm UMRS 1178, CESP, Team "Depression and antidepressants", Le Kremlin-Bicêtre, France, Dispositif Territorial Paris-Sud, DTRF, Paris-Sud, France.

MeSH

AgedAged, 80 and overAgingHumansLithiumNeurodegenerative DiseasesNeuroprotective Agents

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29400298

Citation

Morlet, Élise, et al. "Neuroprotective Effects of Lithium: what Are the Implications in Humans With Neurodegenerative Disorders?" Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement, vol. 16, no. 1, 2018, pp. 78-86.
Morlet É, Hozer F, Costemale-Lacoste JF. Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders? Geriatr Psychol Neuropsychiatr Vieil. 2018;16(1):78-86.
Morlet, É., Hozer, F., & Costemale-Lacoste, J. F. (2018). Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders? Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement, 16(1), 78-86. https://doi.org/10.1684/pnv.2017.0718
Morlet É, Hozer F, Costemale-Lacoste JF. Neuroprotective Effects of Lithium: what Are the Implications in Humans With Neurodegenerative Disorders. Geriatr Psychol Neuropsychiatr Vieil. 2018 Mar 1;16(1):78-86. PubMed PMID: 29400298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders? AU - Morlet,Élise, AU - Hozer,Franz, AU - Costemale-Lacoste,Jean-François, PY - 2018/2/6/pubmed PY - 2018/9/28/medline PY - 2018/2/6/entrez KW - lithium KW - neurodegenerative disorders KW - neuroprotection SP - 78 EP - 86 JF - Geriatrie et psychologie neuropsychiatrie du vieillissement JO - Geriatr Psychol Neuropsychiatr Vieil VL - 16 IS - 1 N2 - Lithium is used as a first line treatment in bipolar disorder. The neuroprotective effects of lithium in this indication tend to be well known and are mediated by its action on two enzymes: glycogen synthase kinase-3 and inositol monophosphatase-1. Preclinical and clinical studies seek to evaluate the neuroprotective effect of lithium in neurodegenerative disorders. The aims of this literature review is to gather clinical studies that investigated the efficacy of lithium in neurodegenerative diseases, using a systematic method based on PubMed data. Results were found concerning Alzheimer's disease and related dementias, Huntington's disease, amyotrophic lateral sclerosis and spino-cerebellar ataxia. Lithium exposure showed a potential neuroprotective effect in studies on psychiatric populations with a lower prevalence of Alzheimer's disease in exposed patients. In patients with mild cognitive impairment, lithium would be associated with clinical improvement and a lower level of cerebrospinal phosphorylated tau protein. Lithium would allow at least a partial improvement in symptoms, including suicidal thoughts, in Huntington's disease. Despite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis. In spinocerebellar ataxia, introduction of lithium may be of benefits in terms of improvement of cerebellar symptoms. Large randomized controlled trials are required to asses the effect of early exposure lithium in these indications, based on reliable biological markers of disease. SN - 2115-7863 UR - https://www.unboundmedicine.com/medline/citation/29400298/Neuroprotective_effects_of_lithium:_what_are_the_implications_in_humans_with_neurodegenerative_disorders DB - PRIME DP - Unbound Medicine ER -